Wendell David Associates Inc. Invests $527,000 in Waters Corporation $WAT

Wendell David Associates Inc. acquired a new stake in shares of Waters Corporation (NYSE:WAT) during the 1st quarter, Holdings Channel reports. The fund acquired 1,770 shares of the medical instruments supplier’s stock, valued at approximately $527,000.

A number of other large investors also recently modified their holdings of the company. Pinnacle Associates Ltd. boosted its holdings in Waters by 0.3% in the 4th quarter. Pinnacle Associates Ltd. now owns 7,608 shares of the medical instruments supplier’s stock worth $2,890,000 after buying an additional 26 shares during the period. Exencial Wealth Advisors LLC raised its holdings in Waters by 1.7% during the fourth quarter. Exencial Wealth Advisors LLC now owns 1,681 shares of the medical instruments supplier’s stock valued at $638,000 after acquiring an additional 28 shares during the period. Rosenberg Matthew Hamilton raised its holdings in Waters by 8.8% during the fourth quarter. Rosenberg Matthew Hamilton now owns 359 shares of the medical instruments supplier’s stock valued at $136,000 after acquiring an additional 29 shares during the period. Clearstead Advisors LLC lifted its position in shares of Waters by 5.1% in the fourth quarter. Clearstead Advisors LLC now owns 616 shares of the medical instruments supplier’s stock valued at $234,000 after acquiring an additional 30 shares in the last quarter. Finally, Integrated Wealth Concepts LLC lifted its position in shares of Waters by 2.9% in the first quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier’s stock valued at $386,000 after acquiring an additional 30 shares in the last quarter. Hedge funds and other institutional investors own 94.01% of the company’s stock.

Waters Stock Up 1.9%

WAT opened at $375.90 on Wednesday. The firm has a 50-day simple moving average of $348.94 and a two-hundred day simple moving average of $346.95. Waters Corporation has a 52 week low of $275.05 and a 52 week high of $414.15. The company has a market capitalization of $36.91 billion, a PE ratio of 47.76, a price-to-earnings-growth ratio of 2.23 and a beta of 1.21. The company has a quick ratio of 1.13, a current ratio of 1.79 and a debt-to-equity ratio of 0.32.

Waters (NYSE:WAT) last issued its earnings results on Tuesday, May 5th. The medical instruments supplier reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.31 by $0.39. Waters had a return on equity of 15.60% and a net margin of 11.91%.The firm had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.20 billion. During the same period in the previous year, the firm posted $2.25 earnings per share. The business’s revenue was up 91.4% compared to the same quarter last year. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. Analysts forecast that Waters Corporation will post 14.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on WAT. TD Cowen upped their price objective on Waters from $345.00 to $385.00 and gave the stock a “hold” rating in a research note on Wednesday, May 6th. Barclays lifted their target price on Waters from $400.00 to $425.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Robert W. Baird set a $387.00 price target on Waters in a report on Wednesday, May 6th. Piper Sandler began coverage on Waters in a research note on Thursday, June 11th. They issued a “neutral” rating and a $400.00 price target for the company. Finally, Wells Fargo & Company increased their price objective on shares of Waters from $355.00 to $370.00 and gave the company an “equal weight” rating in a report on Thursday, May 14th. Four equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, Waters has a consensus rating of “Moderate Buy” and a consensus price target of $396.68.

Waters Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.